GO:0001812 positive regulation of type I hypersensitivity: Immune Activation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001812 describes any process that activates or increases the frequency, rate or extent of type I hypersensitivity, an IgE-mediated inflammatory response.
• Type I hypersensitivity is driven by allergen cross-linking of IgE bound to FcεRI on mast cells and basophils, triggering degranulation and release of histamine and lipid mediators.
• Positive regulation of this process involves amplification loops including epithelial cytokines (IL-25, IL-33, TSLP), IL-17A, and lipid mediators that lower activation thresholds.
• Key effector genes include FCER1A, MS4A2, HDC, CMA1, TPSAB1, IL4, IL13, and SIRT6, which modulate mast cell and epithelial responses.
• Dysregulated positive regulation underlies allergic rhinitis, chronic spontaneous urticaria, asthma, and anaphylaxis, making it a target for therapeutic intervention.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal dissection of genes that amplify type I hypersensitivity.
Description
Type I hypersensitivity is the rapid, IgE-mediated inflammatory reaction that underlies allergic rhinitis, asthma, urticaria, and anaphylaxis. The Gene Ontology term GO:0001812, positive regulation of type I hypersensitivity, captures any process that activates or increases the frequency, rate, or extent of this response. This term is essential for annotating gene products that amplify allergic inflammation, from IgE receptor signaling components to epithelial alarmins and lipid mediators. Understanding positive regulation is clinically urgent because excessive amplification leads to chronic spontaneous urticaria and severe allergic airway disease. Recent therapeutic advances, including plasma kallikrein inhibitors and JAK1 inhibitors, highlight the value of targeting amplification nodes in this pathway. This article integrates the QuickGO definition with verified PubMed literature to provide a research-grade overview of the genes, mechanisms, and CRISPR models relevant to GO:0001812.
positive regulation of type I hypersensitivity At A Glance
| GO ID | GO:0001812 |
|---|---|
| GO term | positive regulation of type I hypersensitivity |
| Ontology | biological_process |
| Synonym | activation of type I hypersensitivity; stimulation of type I hypersensitivity; up regulation of type I hypersensitivity; up-regulation of type I hypersensitivity; upregulation of type I hypersensitivity |
| Major function | Amplification of IgE-mediated inflammatory responses |
| Cellular context | Mast cells, basophils, epithelial cells, and sensory neurons |
| Key mediators | Histamine, leukotrienes, prostaglandins, IL-4, IL-13, IL-17A |
| Disease relevance | Allergic rhinitis, chronic urticaria, asthma, anaphylaxis |
What Is GO:0001812?
GO:0001812, positive regulation of type I hypersensitivity, is defined by QuickGO as any process that activates or increases the frequency, rate or extent of type I hypersensitivity, a type of inflammatory response. In practical terms, it encompasses molecular events that enhance the initiation, magnitude, or persistence of IgE-dependent mast cell and basophil activation, leading to increased release of histamine, lipid mediators, and cytokines.
Why Is positive regulation of type I hypersensitivity Important in Cell Biology?
Positive regulation of type I hypersensitivity is a central node in allergic disease pathogenesis because it determines whether a sensitized individual mounts a mild local reaction or a life-threatening systemic response. The term provides a standardized framework for annotating genes that amplify IgE-dependent inflammation, enabling cross-study comparison and target prioritization. Clinically, excessive positive regulation is associated with chronic spontaneous urticaria and severe allergic airway inflammation, conditions with substantial unmet needs. Emerging therapies such as sebetralstat and abrocitinib demonstrate that interrupting amplification pathways can provide clinical benefit.
• Defines the molecular amplification of IgE-mediated allergic inflammation.
• Links epithelial alarmins and IL-17A to mast cell activation thresholds.
• Provides a framework for annotating genes in allergic rhinitis and urticaria.
• Supports target discovery for anti-allergic therapeutics.
• Enables standardized nasal allergen challenge readouts in clinical research.
• Highlights evolutionary trade-offs of IgE-mediated immunity.
• Guides CRISPR-based causal validation of candidate amplifiers.
• Facilitates cross-species comparison of type I hypersensitivity mechanisms.
• Informs biomarker development for chronic urticaria.
• Connects lipid mediator biology to allergic effector cell function.
What Happens During positive regulation of type I hypersensitivity?
Sensitization and IgE Production
In simple terms: The immune system first learns to recognize an allergen by making IgE antibodies against it.
Positive regulation begins with enhanced IgE class switching in B cells, driven by IL-4 and IL-13 from T follicular helper cells and innate lymphoid cells. This phase increases the density of allergen-specific IgE, which binds to FcεRI on mast cells and basophils, effectively raising the sensitivity of the system to subsequent allergen exposure.
Mast Cell and Basophil Activation
In simple terms: When the allergen appears again, it cross-links IgE on mast cells, causing them to release inflammatory chemicals.
Allergen-mediated cross-linking of FcεRI-bound IgE triggers Lyn and Syk kinase signaling, calcium influx, and degranulation, releasing histamine and proteases. Positive regulation can lower the threshold for this activation through lipid mediators such as leukotrienes and prostaglandins, which amplify vascular permeability and smooth muscle contraction.
Epithelial Amplification Loops
In simple terms: Barrier cells release alarm signals that make the allergic reaction stronger.
Epithelial cells exposed to allergens release IL-25, IL-33, and TSLP, which activate innate lymphoid cells and dendritic cells to promote type 2 inflammation. SIRT6 in epithelial cells has been shown to govern IL-17A pathogenicity and drive allergic airway inflammation and remodeling, illustrating how epithelial regulators can positively regulate type I hypersensitivity.
Lipid Mediator Synthesis and Action
In simple terms: Fat-derived signals prolong and spread the allergic reaction.
Activated mast cells and eosinophils synthesize leukotrienes, prostaglandins, and platelet-activating factor, which recruit additional effector cells and sustain inflammation. These lipid mediators act as positive regulators by increasing vascular permeability, mucus secretion, and bronchoconstriction, thereby enhancing the frequency and extent of type I hypersensitivity responses.
Neuronal and Vascular Amplification
In simple terms: Nerves and blood vessels respond to allergic signals and make symptoms worse.
Sensory neurons activated by histamine and lipid mediators release neuropeptides that promote vasodilation and itch, while endothelial cells upregulate adhesion molecules that recruit leukocytes. This neurovascular amplification loop increases the rate and extent of the inflammatory response, consistent with the GO:0001812 definition.
Key Genes Involved in GO:0001812 positive regulation of type I hypersensitivity
The following genes encode proteins that positively regulate type I hypersensitivity through IgE production, mast cell activation, epithelial alarmin signaling, or lipid mediator synthesis.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FCER1A | High-affinity IgE receptor alpha chain | Mast cell activation threshold |
| MS4A2 | FcεRI beta chain signal amplifier | Amplifies Syk signaling |
| HDC | Histamine synthesis | Histamine release in urticaria |
| CMA1 | Chymase protease | Mast cell degranulation |
| TPSAB1 | Tryptase protease | Anaphylaxis biomarker |
| IL4 | IgE class switching | Type 2 inflammation |
| IL13 | IgE production and mucus | Airway remodeling |
| IL17A | Neutrophilic inflammation | Epithelial SIRT6 axis |
| SIRT6 | Epithelial regulator of IL-17A | Allergic airway inflammation |
| LRRC8A | NADPH oxidase-mediated inflammation | Allergic rhinitis |
| TSLP | Epithelial alarmin | Mast cell priming |
| IL33 | Alarmin activating ILC2s | Type 2 amplification |
| IL25 | Alarmin activating ILC2s | Epithelial-immune crosstalk |
| ALOX5 | Leukotriene synthesis | Lipid mediator pathway |
| PTGS2 | Prostaglandin synthesis | Inflammatory amplification |
| PLA2G4A | Arachidonic acid release | Lipid mediator precursor |
| SYK | Mast cell signaling kinase | FcεRI downstream |
| LYN | FcεRI proximal kinase | Initiation of degranulation |
How Is positive regulation of type I hypersensitivity Regulated?
Positive regulation of type I hypersensitivity is controlled at multiple levels. Epithelial SIRT6 modulates IL-17A pathogenicity and drives allergic airway inflammation, acting as a checkpoint on amplification. Lipid mediators such as leukotrienes and prostaglandins provide positive feedback that sustains mast cell and eosinophil activation. The evolutionary persistence of IgE-mediated responses suggests that regulatory mechanisms balance protective immunity against parasites with pathological hypersensitivity. Therapeutic regulation via plasma kallikrein inhibition or JAK1 inhibition can dampen amplification loops in urticaria and atopic dermatitis.
positive regulation of type I hypersensitivity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LRRC8A | Allergic rhinitis | Knockout mouse or human nasal epithelial cells |
| SIRT6 | Allergic airway inflammation | Epithelial-specific knockout mouse |
| FCER1A | Chronic urticaria | Mast cell knock-in reporter |
| IL4 | Atopic dermatitis | Overexpression mouse model |
| ALOX5 | Asthma | Point mutation knock-in for lipid mediator flux |
Allergic Rhinitis
Allergic rhinitis is a classic type I hypersensitivity disorder in which positive regulation amplifies nasal inflammation. LRRC8A drives NADPH oxidase-mediated mitochondrial dysfunction and inflammation in allergic rhinitis, identifying a specific amplifier. Standardized nasal allergen challenges are used to quantify these responses in clinical research.
Chronic Spontaneous Urticaria
Chronic spontaneous urticaria involves mast cell activation and histamine release, with unmet clinical needs in treatment. Positive regulation of type I hypersensitivity contributes to wheal and flare responses, and therapies such as sebetralstat target amplification pathways.
Allergic Asthma and Airway Remodeling
Epithelial SIRT6 governs IL-17A pathogenicity and drives allergic airway inflammation and remodeling, demonstrating how positive regulation promotes chronic structural changes. Lipid mediators further amplify bronchoconstriction and mucus production.
Atopic Dermatitis
Atopic dermatitis shares type I hypersensitivity mechanisms, and JAK1 inhibition with abrocitinib reduces inflammatory amplification. The evolutionary context of IgE-mediated responses helps explain why these pathways are conserved.
From positive regulation of type I hypersensitivity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X amplify mast cell degranulation? | Knockout in human mast cell line (LAD2) |
| Does a point mutation alter FcεRI signaling? | Point mutation knock-in in RBL-2H3 cells |
| Does epithelial SIRT6 regulate IL-17A? | Epithelial-specific knockout mouse |
| Does LRRC8A drive allergic rhinitis? | Knockout mouse with nasal allergen challenge |
| Does overexpression of IL-13 worsen airway remodeling? | Transgenic overexpression mouse |
| Does a candidate enhancer regulate FCER1A? | CRISPRi/CRISPRa in primary basophils |
How to Study the positive regulation of type I hypersensitivity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Nasal allergen challenge | In vivo hypersensitivity response | Clinical phenotyping |
| Beta-hexosaminidase assay | Mast cell degranulation | Drug screening |
| Histamine ELISA | Histamine release | Urticaria studies |
| LC-MS/MS lipidomics | Leukotriene and prostaglandin levels | Pathway analysis |
| RNA-seq | Transcriptional amplification signatures | Gene discovery |
| CRISPR knockout screen | Candidate amplifier genes | Functional genomics |
| Proximity ligation assay | FcεRI signaling complexes | Mechanistic studies |
Nasal Allergen Challenge
Standardized nasal allergen challenges quantify type I hypersensitivity responses in vivo and are essential for clinical studies of positive regulation.
Mast Cell Degranulation Assays
Beta-hexosaminidase release and histamine measurement in mast cell lines assess functional amplification of FcεRI signaling.
Lipid Mediator Profiling
LC-MS/MS quantification of leukotrienes and prostaglandins reveals the contribution of lipid mediators to positive regulation.
Epithelial-Immune Co-culture
Co-culture of epithelial cells with mast cells or ILC2s models alarmin-driven amplification loops involving TSLP, IL-25, and IL-33.
How CRISPR Can Be Used to Study GO:0001812 positive regulation of type I hypersensitivity
Knockout
CRISPR knockout of candidate genes such as LRRC8A or SIRT6 in mast cells or epithelial cells can determine whether they are required for positive regulation of type I hypersensitivity.
Point Mutation
Point mutation knock-in can model human variants in FCER1A or MS4A2 that alter IgE receptor signaling and amplify degranulation.
Knock-in
Knock-in of reporter tags or humanized alleles into mouse loci enables tracking of mast cell activation and IgE production in vivo.
Overexpression
Overexpression of IL4, IL13, or TSLP in mouse airways can drive type I hypersensitivity amplification and airway remodeling.
How EDITGENE Supports positive regulation of type I hypersensitivity Research
Researchers studying positive regulation of type I hypersensitivity-related genes often need to determine whether a candidate gene is causally involved in amplifying IgE-mediated inflammation. EDITGENE provides CRISPR-based cell models and screening services to validate these hypotheses with publication-ready data.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of type I hypersensitivity research.
Frequently Asked Questions About positive regulation of type I hypersensitivity
What is GO:0001812?
GO:0001812 is the Gene Ontology term for positive regulation of type I hypersensitivity, describing processes that increase the frequency, rate, or extent of IgE-mediated allergic inflammation.
What genes are involved in positive regulation of type I hypersensitivity?
Key genes include FCER1A, MS4A2, HDC, CMA1, TPSAB1, IL4, IL13, IL17A, SIRT6, and LRRC8A.
What is type I hypersensitivity?
Type I hypersensitivity is an IgE-mediated inflammatory response triggered by allergen cross-linking of IgE on mast cells and basophils.
How is positive regulation of type I hypersensitivity studied?
Researchers use nasal allergen challenges, mast cell degranulation assays, lipidomics, and CRISPR screens.
What diseases involve positive regulation of type I hypersensitivity?
Allergic rhinitis, chronic spontaneous urticaria, asthma, and atopic dermatitis are major associated diseases.
What is the role of SIRT6 in allergic airway inflammation?
Epithelial SIRT6 governs IL-17A pathogenicity and drives allergic airway inflammation and remodeling.
How does LRRC8A contribute to allergic rhinitis?
LRRC8A drives NADPH oxidase-mediated mitochondrial dysfunction and inflammation in allergic rhinitis.
What are lipid mediators in type I hypersensitivity?
Lipid mediators such as leukotrienes and prostaglandins amplify vascular permeability and recruit effector cells.
Can CRISPR be used to study type I hypersensitivity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable causal validation of amplifier genes.
What is the evolutionary significance of IgE-mediated hypersensitivity?
IgE-mediated responses likely evolved for parasite defense, with trade-offs that predispose to allergy.
Conclusion
GO:0001812 positive regulation of type I hypersensitivity provides a precise ontological framework for studying the amplification of IgE-mediated allergic inflammation. The integration of epithelial alarmins, lipid mediators, and mast cell signaling defines multiple intervention points relevant to allergic rhinitis, urticaria, and asthma. CRISPR-based models are indispensable for causal validation of these amplifiers and for accelerating therapeutic discovery. As new therapies emerge, targeting positive regulation will remain a central strategy in allergy research.
References
- 1. Augé J et al.. 2018. EAACI Position paper on the standardization of nasal allergen challenges.. Allergy 73(8):1597-1608 PMID: 29377177
- 2. Meng L et al.. 2024. LRRC8A drives NADPH oxidase-mediated mitochondrial dysfunction and inflammation in allergic rhinitis.. J Transl Med 22(1):1034 PMID: 39550567
- 3. Maurer M et al.. 2011. Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report.. Allergy 66(3):317-30 PMID: 21083565
- 4. Blair HA. 2025. Sebetralstat: First Approval.. Drugs 85(11):1499-1505 PMID: 41014446
- 5. Deeks ED et al.. 2021. Abrocitinib: First Approval.. Drugs 81(18):2149-2157 PMID: 34807428
- 6. Quan J et al.. 2023. Epithelial SIRT6 governs IL-17A pathogenicity and drives allergic airway inflammation and remodeling.. Nat Commun 14(1):8525 PMID: 38135684
- 7. Nakamura T. 2021. The roles of lipid mediators in type I hypersensitivity.. J Pharmacol Sci 147(1):126-131 PMID: 34294363
- 8. Pritchard DI et al.. 2021. The evolution of IgE-mediated type I hypersensitivity and its immunological value.. Allergy 76(4):1024-1040 PMID: 32852797
